Viva Biotech is acknowledged for its pioneering AI-driven drug discovery platforms that accelerate timelines, reduce costs, and expand therapeutic innovation in the global pharmaceutical R&D ecosystem.

SAN ANTONIO, Sept. 29, 2025 /PRNewswire/ — Frost & Sullivan is pleased to announce that Viva Biotech has been given the 2025 APAC Technology Innovation Leadership recognition in the Integrated Intelligent Drug Discovery industry for its outstanding achievements in driving transformative efficiencies in preclinical research and development. This recognition highlights Viva Biotech’s consistent leadership in combining artificial intelligence with laboratory-driven validation to reshape the future of drug discovery, strengthen client partnerships, and deliver scalable innovation in a highly competitive landscape.

This recognition highlights Viva Biotech’s consistent leadership in combining artificial intelligence with laboratory-driven validation to reshape the future of drug discovery, strengthen client partnerships, and deliver scalable innovation in a highly competitive landscape.

Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution.

Viva Biotech excelled in both, demonstrating an ability to align advanced technologies with client demand, precisely and at scale. “By integrating multimodal artificial intelligence with extensive wet lab validation, Viva Biotech has established one of the most versatile discovery platforms in the industry. Its ability to support diverse modalities—from small molecules and antibodies to emerging therapies such as PROTACs, molecular glues, and RNA-targeting compounds—significantly reduces development timelines and costs for global clients,” said Priyanka Jain, senior research analyst at Frost & Sullivan.

Guided by a long-term growth strategy that emphasizes digital innovation, client partnerships, and operational efficiency, Viva Biotech has demonstrated remarkable agility in adapting to the evolving pharmaceutical research landscape. The company’s investment in AI-driven modeling, structure-based drug discovery, and seamless lab-in-the-loop systems has enabled it to accelerate decision-making and support first-in-class as well as fast-follow programs for clients worldwide.

Innovation is central to Viva Biotech’s approach. Its Artificial Intelligence-Driven Drug Discovery (AIDD) platform, comprising proprietary modules V-Scepter, V-Orb, and V-Mantle, addresses longstanding drug design challenges by combining predictive modeling, physics-based simulations, and generative AI. These tools are directly integrated with wet lab experimentation, allowing for rapid validation and iterative refinement of drug candidates. “We are very honored to receive this award from Frost & Sullivan,” said Dr.Derek Ren, CEO of Viva Biotech (Shanghai) Ltd. “This recognition validates our vision of building a truly integrated platform that unites AI-driven drug discovery (AIDD) with structure-based drug design (SBDD). The company’s AI platform is transforming the once-impossible into achievable breakthroughs. In future, we will continue accelerate the pace of AI-driven drug discovery and development and lead in a new era of scientific innovation.”

Viva Biotech’s unwavering commitment to client experience further enhances its global position. By offering flexible collaboration models and milestone-based agreements while ensuring full ownership of intellectual property for its partners, the company delivers clear value and fosters long-term trust. Its integrated service capabilities not only reduce project risks but also empower clients to explore emerging modalities with confidence, speed, and scientific rigor.

Frost & Sullivan commends Viva Biotech for setting a benchmark in technological innovation, strategic execution, and customer-centric growth. The company’s AI-first methodology, supported by world-class expertise in structural biology and preclinical experimentation, is shaping the evolution of integrated intelligent drug discovery and enabling measurable outcomes across therapeutic areas.

Each year, Frost & Sullivan presents the Technology Innovation Leadership recognition to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. This recognition celebrates forward-looking organizations that are redefining their industries through transformative innovation and growth excellence.

Frost & Sullivan Best Practices Recognition

Frost & Sullivan’s Best Practices Recognitions honor companies across regional and global markets that exhibit exceptional achievement and consistent excellence in areas such as leadership, technological innovation, customer experience, and strategic product development. Each recognition is the result of a rigorous analytical process in which Frost & Sullivan industry experts benchmark performance through comprehensive interviews, deep-dive analysis, and extensive secondary research. The goal is to identify true best-in-class organizations that are driving transformative growth and setting new industry standards.

Contact us: Start the discussion.

Contact:

Tarini Singh
E: Tarini.Singh@frost.com 

About Viva Biotech

Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial manufacturing to global biopharmaceutical innovators. We offer leading early-stage to late-phase drug discovery expertise by integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, DEL, ASMS, SPR, HDX, AIDD/CADD, and much more. Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics across the pharma and biotech spectrum. The experienced chemistry team, led by senior medicinal chemists and drug discovery biologists, provides services for drug design, medicinal chemistry (hit to lead and lead optimization), custom synthesis, chemical analysis and purification, kilogram scale-up, peptide synthesis and corresponding bioassays. With our subsidiary, Langhua Pharma, we offer our worldwide pharmaceutical and biotech partners a one-stop integrated CMC (Chemical, Manufacturing, and Control) service from preclinical to commercial manufacturing. Additionally, Viva embedded an equity for service (EFS) model to high potential startups to address unmet medical needs.

To learn more about Viva Biotech, please visit https://www.vivabiotech.com or contact at marketing@vivabiotech.com.

GUANGZHOU, China, Sept. 29, 2025 /PRNewswire/ — On September 23, the 2025 China Catering Brand Festival (34th HCC Catering Industry Expo), guided by the Guangzhou Municipal Bureau of Commerce and co-hosted by the World Association of Chinese Cuisine and HongCan, officially kicked off. As a highlight of the festival, the 2025 Trendsetting Products (Autumn) Global Launch was successfully held in Guangzhou.

As a flagship segment of the festival, the launch convened an impressive lineup of industry leaders — including founders of prominent F&B brands, executives from leading supply chain enterprises, renowned experts, and association representatives. The event was also attended by authoritative media and key opinion leaders, with several top-tier influencers from the Hongdongshike Influencer Alliance adding to the event’s influence and visibility.

The launch drew significant international attention as well, with media outlets from Italy, France, the United Kingdom, Southeast Asia, and other regions covering the event, further amplifying its impact and extending the global reach of the brand.

The conference showcased a diverse range of outstanding products that are driving industry trends. In the “Revolutionizing Taste” segment, featured products such as Juhui Food Technology (Chongqing) Co.,LTD’s Laoyouji hotpot sauce1983, KINGWELL Extra Savory & Mellow Agaricus Blazei Mushroom Soup Base, Sichuan Cuihong BBQ Powder, and Jiangsu Meixin Food Technology Co.., Ltd’s Fig and Chicken Broth Flavor Soup Base demonstrated the limitless possibilities of expanding the culinary experience.

In the “Elevating Quality” segment, McCormick’s Cajun seasoning, Baipinriguang Golden Tomato Seasoning, Dai Xia Ji Whole Shrimp Bite-Size Paste, and JIACHUANG FOOD’s Tomahawk Steak highlighted breakthroughs in quality and refinement.

In the “Reinventing the Classics” segment, Evergreen Food’s Evergreen Squirrel-Shaped Tilapia, ZAIQI Grain Stalpes “Yellow Steamed Buns,” SUNBOY (InnerMongolia) Food Technology Group Co., LTD.’s Roasted Sunflower Seeds Original Flavor Gift Package, and KEENON ‘s Dinerbot t10 showcased innovative approaches to reimagining traditional forms and applications.

To recognize the pioneering role and innovation of the Trendsetting Products, the 2025 Trendsetting Products (Autumn) Global Launch Conference also featured an awards ceremony. Two honors were presented — the “Trend Leadership Award” and the “Breakthrough Innovation Award,” with winners selected based on four key dimensions: innovation, market potential, quality consistency, and scenario adaptability.

The 2025 Trendsetting Products (Autumn) Global Launch Conference serves as the premier global stage this autumn for unveiling China’s latest F&B products, technologies, and concepts, and also as a vital platform propelling the industry toward standardization, branding, and internationalization. By continuously providing guidance on product selection and setting new paradigms for innovation, the conference empowers brands and enterprises to seize market opportunities and achieve sustainable growth.

BANGKOK, Sept. 29, 2025 /PRNewswire/ — Chula ARi, an interdisciplinary initiative by Chulalongkorn University, addresses the challenges of Thailand’s rapidly aging society by using research to develop comprehensive elderly care models across economic, social, health, environmental, and innovation dimensions. The project also encourages pre-senior citizens to prepare for future aging challenges.

Thailand is approaching a “senior tsunami,” with the population aged 60 and above expected to rise from 20% to 30% within the next decade, transforming the nation into a super-aged society. Professor Dr. Vipan Prachuabmoh, project director, explains that the large population born between 1963–1983 will contribute nearly one million new elderly annually. Longer life expectancies, combined with chronic diseases and dependence, pose societal and welfare challenges.

Launched in 2018 with C2F funding, Chula ARi aims to enhance the elderly’s quality of life and prepare society for aging. Thailand faces unique pressures due to low birth rates and limited elderly support infrastructure compared to nations like Japan and Korea. The project emphasizes collaboration, community engagement, and actionable research across multiple disciplines, including medicine, engineering, architecture, and social sciences.

Chula ARi operates on three levels: conducting policy-driven research, raising public awareness, and piloting community-focused elderly support initiatives. The project has developed master plans for national and Bangkok-specific elderly action strategies. Between 2018–2022, ten urban communities in Bangkok were piloted, implementing health programs, home adaptations, green spaces, and learning centers. Surplus vegetable gardens generated income, and communal facilities fostered intergenerational interaction.

Technology, particularly robots, plays a critical role in elderly care. Rehabilitation robots, telemedicine devices, and limb therapy systems have been deployed in several Bangkok communities to improve the efficiency and accessibility of care. Building on these successes, Chula ARi expanded to 15 additional Bangkok communities, collaborating with the Bangkok Metropolitan Administration and regional universities to form Thai-ARi, extending support systems nationwide.

The project emphasizes future planning for pre-senior citizens, encouraging lifelong learning, health management, financial preparation, and mental resilience to navigate crises. Care for the elderly focuses on three dimensions—mind, body, and environment—promoting emotional support, active lifestyles, nutrition, and safe, accessible living spaces.

Chula ARi exemplifies a holistic, research-driven, and community-centered approach to aging, aiming to create sustainable urban elderly communities and serve as a model for Thailand and beyond.

Read the full article at https://www.chula.ac.th/en/highlight/261295/

BANGKOK, Sept. 29, 2025 /PRNewswire/ — Chula ARi, an interdisciplinary initiative by Chulalongkorn University, addresses the challenges of Thailand’s rapidly aging society by using research to develop comprehensive elderly care models across economic, social, health, environmental, and innovation dimensions. The project also encourages pre-senior citizens to prepare for future aging challenges.

Thailand is approaching a “senior tsunami,” with the population aged 60 and above expected to rise from 20% to 30% within the next decade, transforming the nation into a super-aged society. Professor Dr. Vipan Prachuabmoh, project director, explains that the large population born between 1963–1983 will contribute nearly one million new elderly annually. Longer life expectancies, combined with chronic diseases and dependence, pose societal and welfare challenges.

Launched in 2018 with C2F funding, Chula ARi aims to enhance the elderly’s quality of life and prepare society for aging. Thailand faces unique pressures due to low birth rates and limited elderly support infrastructure compared to nations like Japan and Korea. The project emphasizes collaboration, community engagement, and actionable research across multiple disciplines, including medicine, engineering, architecture, and social sciences.

Chula ARi operates on three levels: conducting policy-driven research, raising public awareness, and piloting community-focused elderly support initiatives. The project has developed master plans for national and Bangkok-specific elderly action strategies. Between 2018–2022, ten urban communities in Bangkok were piloted, implementing health programs, home adaptations, green spaces, and learning centers. Surplus vegetable gardens generated income, and communal facilities fostered intergenerational interaction.

Technology, particularly robots, plays a critical role in elderly care. Rehabilitation robots, telemedicine devices, and limb therapy systems have been deployed in several Bangkok communities to improve the efficiency and accessibility of care. Building on these successes, Chula ARi expanded to 15 additional Bangkok communities, collaborating with the Bangkok Metropolitan Administration and regional universities to form Thai-ARi, extending support systems nationwide.

The project emphasizes future planning for pre-senior citizens, encouraging lifelong learning, health management, financial preparation, and mental resilience to navigate crises. Care for the elderly focuses on three dimensions—mind, body, and environment—promoting emotional support, active lifestyles, nutrition, and safe, accessible living spaces.

Chula ARi exemplifies a holistic, research-driven, and community-centered approach to aging, aiming to create sustainable urban elderly communities and serve as a model for Thailand and beyond.

Read the full article at https://www.chula.ac.th/en/highlight/261295/